Objective: Conventional open surgery encompassing cardiopulmonary bypass has been traditionally used for the treatment of ascending aorta diseases. However, more than one in five of these patients will be finally considered unfit for open repair. We conducted a systematic review and meta-analysis to investigate the role of thoracic endovascular aortic repair (TEVAR) for aortic diseases limited to the ascending aorta.
Diseases of the ascending aorta, like acute type A aortic dissection, intramural hematoma, penetrating atherosclerotic ulcer, and chronic aneurysmatic dilation, have traditionally been treated with conventional open surgery through a median sternotomy and cardiopulmonary bypass, with the majority of them also necessitating circulatory arrest and deep hypothermia. However, 28% of these patients will be considered unfit for open repair. 1 Thoracic endovascular aortic repair (TEVAR) has emerged as a potential alternative to emergency open surgical repair for acute aortic syndromes in selected patients. The feasibility of endovascular ascending aortic repair has been demonstrated in several case reports that used a variety of devices, all originally designed for the descending aorta. 2 TEVAR of the ascending aorta poses a challenge, mainly because of the curvature of the aortic arch, proximal fixation close to the aortic valve and coronary ostia, distal fixation that may impinge on the innominate artery, considerable hemodynamic forces, and risk of cardiac and aortic injury and retrograde aortic dissection. Some of the major complications of this procedure are novel, even to the endovascular specialists who are experienced in aortic endografting; these include perforation of the left ventricle, injury and dissection of the aortic root, and occlusion of the coronary arteries. 3 Nearly all commercially available TEVAR devices are designed for the treatment of descending aortic disease. No device (except for Zenith Ascend TAA Endovascular Graft 4 ; Cook Medical, Bloomington, Ind) has yet been specifically designed for the ascending aorta. To avoid the high risk of operation in patients with comorbidities or a previous cardiothoracic procedure, endografts in the ascending aorta may be a good alternative treatment. Safe and effective implementation of TEVAR in the treatment of ascending aortic diseases may be the solution for less invasive and efficient treatment.
The aim of this systematic review and meta-analysis was to investigate the clinical outcomes of endovascular repair limited to the ascending aorta and not involving the arch vessels. We explored the literature, in terms of both case series and case reports, concerning the mortality and morbidity, the complications, the access, and the techniques of the method.
METHODS

Data collection
The meta-analysis was conducted using the Preferred Reporting Items for Systematic Reviews and MetaAnalyses guidelines. The following medical literature databases were systematically searched: MEDLINE, Scopus, Embase, Google Scholar, Ovid, and the Cochrane Library. A snowball process in the reference lists of the eligible articles was performed after retrieval of the relevant articles from search of the databases.
Search methodology, inclusion and exclusion criteria, and data extraction We used the following Medical Subject Headings terms: ("ascending aorta" [All Fields] OR "zone 0" [All Fields]) AND ("thoracic" [All Fields]) AND ("endovascular" [All Fields]). We searched for all scientific papers, without gender or language restriction, until October 2016. We investigated studies focusing on TEVAR limited to the ascending aorta for all types of aortic diseases. Studies reporting on hybrid thoracic endovascular repair into the ascending aorta were excluded. Two authors (C.N.A., N.A.P.) independently extracted and analyzed the data, and final decision was reached by consensus.
Data extracted from eligible studies included the first author's name, study year, country in which the study was conducted, total number of patients, number of male patients, number of patients with prior cardiac/ aortic surgery, indications for treatment, mean length of in-hospital stay (days), follow-up (months), inclusion and exclusion criteria, vascular access site (transfemoral, transapical, or through the axillary artery), type of anesthesia applied, type of anticoagulation used, type of endograft used, use of transesophageal echocardiography (TEE), and description of complications during follow-up. We also extracted the number of patients with outcomes of interest, which were described as early and late. Early outcomes were defined as outcomes during the first 30 postoperative days 5 or in-hospital outcomes. [6] [7] [8] The majority of the studies included both of these definitions of early outcomes, 4,9-11 so we defined early outcomes as those occurring in 30 days or inhospital outcomes and late ones as those happening beyond this period. Early (30 days/in-hospital stay) outcomes included the following: technical success; conversion to open repair; death; neurologic event; myocardial infarction; respiratory failure requiring tracheostomy, intubation, or prolonged ventilation; renal failure requiring dialysis; any arrhythmia; acute aortic insufficiency, mitral regurgitation, or both; and branch vessel occlusion. Late (beyond 30 days/in-hospital stay) outcomes included endoleak, death, and reoperation.
Statistical analyses
Data synthesis and treatment effects. The outcome rates in patients with TEVAR in the ascending aorta were estimated for each study and reported as the proportion of patients with the corresponding outcome among all patients with TEVAR in the ascending aorta. Values of the concomitant outcomes were subsequently appropriately calculated, expressed as proportions and 95% confidence intervals (CIs), and thereafter transformed into quantities according to the Freeman-Tukey variant of the arcsine square root transformed proportion. The pooled effect estimates were calculated as the back-transformation of the weighted mean of the transformed proportions, using Der Simonian-Laird weights of random-effects model and expressed as percentage proportions. 12 Two separate meta-analyses were conducted. The first derived pooled outcome rates, taking into account all case series (each case series participated with its own outcome rate) plus case reports (one outcome rate was calculated for all case reports). The second analysis derived pooled outcome rates only from case series (sensitivity analysis). Heterogeneity, publication bias, and meta-regression analysis. A formal statistical test for heterogeneity using the I 2 test was performed. Publication bias was assessed using the Egger test for small-study effects as well as visual inspection of funnel plots. We used Stata statistical software version 14 (StataCorp LP, College Station, Tex) for the analyses.
RESULTS
Study characteristics. We identified 398 potentially eligible studies after a literature search. Review of the titles and abstracts evidenced that 211 articles were irrelevant. We also removed 11 articles because they were reviews and not original articles. A total of 176 articles were further evaluated. Finally, 36 articles were deemed relevant to be included in the systematic review. Among them, 13 were case series 2-11,13-15 and 23 were case reports. However, because of overlapping population, we further excluded 6 articles, and finally 30 articles participated in the meta-analysis (Fig 1) , corresponding to a total of 119 patients who underwent TEVAR in the ascending aorta. Baseline study characteristics of the 30 eligible studies included in the systematic review (13 case series and 17 case reports) are presented in Table I for case series  and in Table II Fig 2) ; mortality was 2.9% (95% CI, 0.02-8.6; Fig 3) . We estimated a pooled rate of 1.8% (95% CI, 0.1-7.0) for neurologic events, whereas 0.8% (95% CI, 0.1-5.6) of the pooled study population suffered from myocardial infarction after the procedure. Among the other early outcomes studied, pooled branch vessel (mostly innominate artery Fig 5) of the study sample during follow-up. However, no late conversions to open repair were described. Sensitivity analyses evidenced that technical success was 93.8% (95% CI, 85.6-99.2) for case series and 100.0% (80.5-100.0) for case reports (Fig 2) . Early mortality was 2.8% (95% CI, 0.0-9.0) and 5.9% (95% CI, 0.2-28.7) for case series and case reports, respectively (Fig 3) ; the corresponding pooled rates for late endoleak were 16.7% (95% CI, 7.5-27.8) and 17.7% (95% CI, 3.8-43.3; Fig 4) . Reoperation was estimated with a pooled rate of 7.9% (95% CI, 2.0-15.8) for case series and 17.7% (95% CI, 3.8-43.3) for case reports (Fig 5) .
DISCUSSION
This meta-analysis derived from a comprehensive review of 13 case series and 17 case reports and provided pooled outcome rates for patients treated with TEVAR for aortic disease limited to the ascending aorta and not involving the arch vessels. Although high-risk patients mainly constituted our study cohort, a high technical success rate of 96% and a low early conversion rate of 0.7% were recorded. We estimated that 2.9% of the patients died during the early period, whereas 1.8% and 0.8% of the patients suffered from neurologic events and myocardial infarction, respectively. Although these rates were relatively small, early branch vessel occlusion was estimated at 12%. In the late postoperative period, we recorded a pooled mortality rate of 4.4%. During follow-up, a total of 16.4% of the patients presented with endoleak; almost 9% required a reoperation. Thirteen patients required an additional endovascular procedure to treat endoleaks, whereas only one was treated with open repair. Five patients with endoleak were under surveillance during the follow-up; two of them refused additional treatment. These figures may highlight that although the method is not widely adopted yet and probably is in a learning curve period, it may offer an early advantage to high-risk patients. Our meta-analysis showed a lower pooled mortality rate (2.8%) and need for reoperation (7.9%) for case series compared with higher rates (5.9% and 17.7%, respectively) for case reports, so this procedure seems to be feasible with acceptable risk. We initially thought that case series might report different outcomes compared with case reports. As a result, we opted for two separate meta-analyses (Table III) , one with case series and case reports and a second with case series only. Interestingly, similar results were recorded. Apart from the feasibility of the method, it is logical to support that multidisciplinary teams may provide better outcomes after the learning curve has been stabilized. However, we should bear in mind that early case reports might be reported by big centers and late case series by lower volume centers. Consequently, it was difficult to assess the effect of high volume in our meta-analysis. Morbidity was also low in our pooled cohort of patients. Neurologic events occurred in 1.8% of the patients in case series and in 2.9% in case reports. During transarterial valve implantation (TAVI), the frequency of stroke at 30 days was 5.0% 39 wires and the device may be the reason for neurologic events, and attention must be paid during graft deployment to avoid innominate artery occlusion. Renal dysfunction requiring dialysis was observed in low rates (0.8% in case series and 0.08% in case reports). The postoperative renal failure may be attributed to contrast media during TEVAR in patients with a chronic renal dysfunction. In our meta-analysis, the conversion rate to open surgery was 0.7% in case series and 1.2% in case report studies. During TEVAR in the ascending aorta, it is probably advisable that the extracorporeal circulation be available in case of conversion to open surgical repair. Furthermore, in our meta-analysis, endoleak of any type was observed in 16.4% of the patients, which is close to 18% of endoleak after a typical TEVAR in the descending aorta. 40 It should be highlighted that the absence of side branches in the ascending aorta makes type II endoleak not feasible, whereas in case of only one graft deployed in the ascending aorta, type III endoleak is not possible. As a result, the endoleak rates observed in TEVAR in the ascending aorta may be mainly type Ia and Ib. Our meta-analysis indicated that TEVAR in the ascending aorta was performed most commonly for acute or chronic Stanford type A dissection (48.7%); ascending aortic pseudoaneurysm (27.7%) and ascending aortic aneurysm (9.3%) followed. Looking at the characteristics of the eligible studies revealed that the endovascular procedure was mainly performed in patients at high risk for open surgery, of a broad age group, and with a history of previous open cardiac procedure. Interestingly, in two case series, patients with very high risk by European System for Cardiac Operative Risk Evaluation (EuroSCORE) were included; Ronchey et al 7 reported a EuroSCORE of 37.05 in a patient with previous aortic valve replacement and ascending aorta replacement for type A dissection, and Piffaretti et al 6 reported a EuroSCORE of 23.79 in a patient with a previous Bentall operation. Although high-risk patients composed our pooled cohort, mortality was remarkably low (2.8%). Furthermore, TEVAR in the ascending aorta was a minimally invasive procedure with a mean endovascular intervention time of 120 to 150 minutes compared with lengthy open surgery. Our meta-analysis indicated that the median length of stay was between 3 and 16 days (average, 8.4 days). This was more than the length of stay after endovascular aneurysm repair or TEVAR in the descending aorta, but it is well accepted, given that these patients were of very high risk. As a result, TEVAR in the ascending aorta may be a safe and effective procedure for this cohort of patients. General anesthesia was used in almost all cases for better patient management. TEE was also applied in most of the patients to better visualize the graft and its relation to the surrounding anatomic structures. TEE may be a useful tool because during graft deployment, its proximal and distal position, aortic valve function, and presence of pericardial effusion can be visualized. Moreover, in most patients (>85%), rapid cardiac pacing rather than vena cava occlusion or adenosine infusion was used for more precise graft deployment. According to Lu et al, 8 The ascending aorta has some special characteristics, which include great pulsatility, difference in hemodynamic forces, and restricted length, compared with other parts of the aorta. As a result, grafts shorter than 10 cm were used for ascending aorta TEVAR. Zenith Ascend TAA, which is designed for the ascending aorta, is 65 mm, 4 whereas the length of custom-made stent grafts used in the studies included ranged from only 45 mm to a maximum of 100 mm. Furthermore, it is necessary to use a delivery system that accommodates deployment into curved anatomy and considers crossing the aortic valve or not, particularly when there is a mechanical valve in place. In addition, fragility of the ascending aorta may pose difficulties, with the potential of retrograde dissection from the entry site, 41 Bjaeverskov, Denmark) and incorporates uncovered stents on both the proximal and distal ends to facilitate accurate deployment, alignment, and apposition of the graft in the ascending aorta. However, only Tsilimparis et al 4 reported the use of this stent designed for the ascending aorta for its intended indication.
Although good results after TEVAR in the ascending aorta have been reported, endovascular repair is not feasible for every patient, and anatomic restrictions for the existing nondedicated devices are noted. Proximal and distal landing zones have to be >10 mm, even 20 mm for some authors. The diameter of the ascending aorta has to be between 16 and 42 mm. Absence of calcification or thrombotic material may predispose to sufficient stent graft sealing and avoidance of type I endoleak. Then, in case of acute dissection, the intimal tear has to be >10 mm above the sinotubular junction and >5 mm proximal to the innominate artery, and imaging of the coronary arteries should be considered. Furthermore, adequate access is also important. Our meta-analysis has found that the device delivery system was advanced transfemorally in the majority of the patients (66.7%); less popular access sites included transapical (12.8%), through the carotid artery (6.8%), through the axillary artery (8.5%), and other less common sites. Irrespective of the access site, the common and external iliac artery has to be >7 mm in diameter. Moreover, in case of mechanical or heavily calcified aortic valve, TEVAR is also not feasible. The long nose cone (part of the delivery system) has to pass into the left ventricle through the aortic valve to achieve the appropriate proximal stent graft deployment. In case of severe aortic valve stenosis and a concomitant pathologic process in the ascending aorta, a novel composite graft to repair both endovascularly has been designed, 42 although experience in TAVI and endovascular surgery is mandatory. Furthermore, in patients with Marfan syndrome, in case of aortic valve regurgitation, and in case of annuloaortic ectasia, TEVAR may also not be possible. Another limitation of the method is that the proximal third of this segment is unapproachable by endovascular treatment with the current technology when the aortic valve and coronary arteries are also involved. 2 The distal third, owing to the proximity to supra-aortic branches, frequently requires a hybrid approach. It seems that selection of appropriate patients in the management of ascending aortic diseases remains of utmost importance.
9 Fig 3. Forest plot presenting the meta-analysis of in-hospital mortality based on event rates for case series and case reports. Event rates in the individual studies are presented as squares, with 95% confidence intervals (CIs) presented as extending lines. The pooled event rate with its 95% CI is depicted as a diamond. ES, Effect size.
Limitations. There are several limitations of this study. First, a small number of patients were included in each eligible study. As already known, early in the experience of new surgical techniques, the reports are limited to generally favorable outcomes in small numbers of patients with short follow-up, whereas poor outcomes do not get reported. As a result, there might have been an indirect publication bias in our study. However, by including also case series in our analysis and by assessing publication bias with the Egger test, we aimed to minimize potential sources of publication bias.
Furthermore, the mortality rate of 2.8% as reported in our meta-analysis should be carefully verified in more reliable reports and commented on, considering that the mortality rate in the ascending aorta for TEVAR extending more distally into the arch ranges from 10% to 15%. The same consideration should be given to the 1.8% stroke rate.
Another limitation of our study is the fact that no separate results were provided for each one of the aortic diseases among the eligible studies, as no such data were mentioned in the studies included. However, clinical entities such as penetrating ulcers and chronic dissections are definitely more stable than others, such as acute dissections, potentially leading to different results. There is a large disparity among all patients and the method of reporting regarding the indications, the emergency cases rate, and the modality of treatment (access site, type of induced hypotension), and no information on causes of death and reoperation could be extracted.
CONCLUSIONS
Data concerning TEVAR limited to the ascending aorta and not involving the arch vessels are currently fragmentary without uniform and clear results. 6 Our review and meta-analysis pooled together outcome rates of all relevant studies and highlighted the feasibility of TEVAR in the ascending aorta for various aortic diseases, even in high-risk patients. TEVAR in the ascending aorta is a relatively new technique, and we might need more experience before sound conclusions can be drawn. Although it is early to generalize the results, the first impression is that this technique might be promising for the treatment of ascending aorta disease, which is otherwise difficult to assess openly. Because of the small number of patients, registries are absolutely necessary to expand 
